AZOXIMER BROMIDE ADJUVANT
in Grippol® vaccines allows a 3-fold reduction of antigens, ensuring a pronounced and long-lasting immune response to vaccination
GRIPPOL® PLUS AND GRIPPOL® QUADRIVALENT VACCINES
meet current influenza vaccine quality standards
- Preservative and Antibiotic-free
- Available in individual syringe doses with an atraumatic needle
- Manufacture in accordance with GMP standards
VACCINES GRIPPOL®
are developed with antigen-saving technology. The antigenic composition of vaccines is updated annually in accordance with the recommendations of the World Health Organization
GRIPPOL® VACCINES HAVE A MASSIVE EXPERIENCE OF USE AMONG VARIOUS CATEGORIES OF CITIZENS:
- Children from 6 months and overе
- Adults, elderly people, people with chronic diseases, including cardiovascular and bronchopulmonary diseases, bronchial asthma, chronic kidney disease, diabetes mellitus, allergies, and HIV infections
- Pregnant women
WHAT DO YOU KNOW ABOUT FLU?
Grippol® Plus
Grippol® Plus is a trivalent influenza vaccine containing the antigens of two type A viruses and one type B virus. In addition to the antigens, it also contains azoximer bromide. It acts as an adjuvant, i.e. a substance that stimulates the immune response to antigens when the vaccine is administered, and thus contributes to its effectiveness. The addition of azoximer bromide reduces the number of antigens in the vaccine while maintaining efficacy and improving the safety profile.
Grippol® Plus contains no preservatives or antibiotics, which reduces the risk of local reactions to the vaccination. Due to these properties, Grippol® Plus is indicated for preventive vaccinations for all categories of citizens, including children over 6 months of age, pregnant women, persons with chronic diseases, the elderly, highly allergic individuals, and immunodeficient persons.
The antigenic composition of the Grippol® plus vaccine is updated annually according to WHO recommendations and forecasts of the circulation of influenza virus strains of northern hemisphere influenza season.
Grippol® Quadrivalent
Grippol® Quadrivalent is a quadrivalent vaccine that protects against two strains of type A viruses and two strains of influenza B virus (Victoria and Yamagata). Compared to trivalent vaccines, the addition of the 4th strain to the Grippol® Quadrivalent provides greater protection against influenza virus In both lines. The efficacy of flu vaccination with Grippol® Quadrivalent is due to the content of Polyoxidonium® as an adjuvant. Protecting against more strains of influenza virus, the vaccine has a high safety profile due to its reduced antigen content, as confirmed by clinical trials conducted to world standards.
Grippol® Quadrivalent is available in syringes for single individual use, and is recommended for people aged 6 to 60 with a high risk of influenza infection. These are employees of health care institutions, education and public order services, the military, social and welfare services, catering, trade services, as well as workers and engineers from all sectors of industry.
The vaccine contains no preservatives or antibiotics.